"Hirudins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
| Descriptor ID |
D006629
|
| MeSH Number(s) |
D12.644.861.060.875 D12.776.872.060.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hirudins".
Below are MeSH descriptors whose meaning is more specific than "Hirudins".
This graph shows the total number of publications written about "Hirudins" by people in this website by year, and whether "Hirudins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hirudins" by people in Profiles.
-
Xiao H, Meng X, Li Z, Fang S, Wang Y, Li J, Tang J, Ma L. Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology. Biomaterials. 2024 Dec; 311:122670.
-
Sukumaran M, Cantrell DR, D'Agostino C, Jahromi BS, Ansari SA, Potts MB. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis. 2024 Jun; 33(6):107310.
-
Mallidi J, Ulahannan J, Chaubey VK, Atreya AR, Shakoor MT, Fisher D, Garb J, Lotfi A. Comparison of Clinical Outcomes: Bivalirudin With Transfemoral Access Versus Heparin With Transradial Access in Patients With ST segment Elevation Myocardial Infarction. Crit Pathw Cardiol. 2019 09; 18(3):130-134.
-
Mallidi JR, Robinson P, Visintainer PF, Lotfi AS, Mulvey S, Giugliano GR. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):898-904.
-
Pinto DS, Kohli P, Fan W, Kirtane AJ, Kociol RD, Meduri C, Deliargyris EN, Prats J, Reynolds MR, Stone GW, Michael Gibson C. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. Catheter Cardiovasc Interv. 2016 Feb 15; 87(3):363-73.
-
Sylvia LM, Ordway L, Pham DT, DeNofrio D, Kiernan M. Bivalirudin for treatment of LVAD thrombosis: a case series. ASAIO J. 2014 Nov-Dec; 60(6):744-7.
-
Anand SX, Viles-Gonzalez JF, Mahboobi SK, Heerdt PM. Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition. Can J Anaesth. 2011 Mar; 58(3):296-311.
-
Giugliano GR, Sivalingam SK. Bivalirudin use during PCI for stent thrombosis in a patient with subacute intracranial hemorrhage. J Invasive Cardiol. 2009 Mar; 21(3):136-8.
-
Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008 Nov 25; 52(22):1758-68.
-
Hirbawi J, Bukys MA, Barhoover MA, Erdogan E, Kalafatis M. Role of the acidic hirudin-like COOH-terminal amino acid region of factor Va heavy chain in the enhanced function of prothrombinase. Biochemistry. 2008 Jul 29; 47(30):7963-74.